Longevity Biotech is pleased to announce funding support from the National Multiple Sclerosis Society to our evaluate lead candidate, LBT-3627, as a potential treatment for MS.

Longevity Biotech is pleased to announce funding support from the National Multiple Sclerosis Society to our evaluate lead candidate, LBT-3627, as a potential treatment for MS. - Longevity Biotech Skip to main content Hit enter to search or ESC to close Close Search Newsroom Longevity Biotech is pleased to announce funding support from the National Multiple Sclerosis Society to our evaluate lead candidate, LBT-3627, as a potential treatment for MS. By kappNo Comments October 27, 2017 – Philadelphia, PA Longevity Biotech is pleased to announce funding support from the National Multiple Sclerosis Society to our evaluate lead candidate, LBT-3627, as a potential treatment for MS. Privacy Policy  |  Cookies Policy  |  Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT linkedin

The release as fetched from its publisher. longevitybiotech.com ↗